Health Economics›MALT lymphoma›Relapsed or refractory, non-randomized or retrospective data

Relapsed or refractory, non-randomized or retrospective data

MALT lymphoma · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cladribine and Rituximab Variant #01	—	R 48 077	21d	—	—	~6	~R 288 462 indirect	—
Clarithromycin monotherapy Variant #01	—	R 10 317	21d	—	—	~4	~R 41 268 indirect	—
Bortezomib monotherapy Variant #03	—	R 6 762	21d	~30.3 mo	—	~8	~R 54 096 PFS proxy · indirect	5
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	~30.8 mo	—	~13	~R 28 314 PFS proxy · indirect	2

4 of 4 regimens shown